Comparative Pharmacology
Head-to-head clinical analysis: AMITRIPTYLINE HYDROCHLORIDE versus ELAVIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMITRIPTYLINE HYDROCHLORIDE versus ELAVIL.
AMITRIPTYLINE HYDROCHLORIDE vs ELAVIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits reuptake of serotonin and norepinephrine, leading to increased concentrations at synaptic cleft; also blocks histamine H1, alpha-1 adrenergic, and muscarinic cholinergic receptors.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their synaptic concentrations. It also exhibits anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Oral: 25-150 mg daily in divided doses or as a single bedtime dose; maximum 300 mg/day.
Oral: Initial 75 mg/day in divided doses or 50-100 mg at bedtime; increase to 150 mg/day; maximum 300 mg/day. IM: 20-30 mg q6h, switch to oral as soon as possible.
None Documented
None Documented
Terminal elimination half-life is 15-35 hours (range 9-46 hours); clinical context: steady-state concentrations achieved within 7-10 days; may be prolonged in elderly, hepatic impairment, or CYP2D6 poor metabolizers.
10–50 hours (mean ~20 hours); terminal elimination half-life is prolonged in elderly and patients with hepatic impairment; steady-state achieved in 7–21 days.
Primarily renal (approximately 30-50% as unchanged drug and metabolites, mainly glucuronide conjugates and hydroxylated metabolites). Fecal excretion accounts for <5%. Enterohepatic recirculation may occur.
Renal (approximately 40% as metabolites, <5% unchanged); biliary/fecal (approximately 60% as metabolites, including glucuronide conjugates).
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant